NCT07486986Not yet recruiting
Endocrine Disruption, Menopause, and Poor Sleep in wOmen With Type 2 Diabetes: Effects on Cardiovascular Health
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
EMPOWER aims to determine the overall effect of menopause and sleep disruption on cardiac remodeling in women with type 2 diabetes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 381 (estimated)
- First submitted
- 17 Mar 2026
- Start date
- Dec 2026
- Primary completion date
- Dec 2032
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Diseases
- Type 2 diabetes
- NCT number
- NCT07486986
What you commit to
- Study type: Observational
- Planned participants: 381
- From Dec 2026 to the primary completion date, Dec 2032
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of total hysterectomy or bilateral oophorectomy
- Prior diagnosis of any of the following:
- Coronary Vascular Disease (CVD) including coronary heart disease, heart failure, congenital heart disease stroke/transient ischemic attack, valvular heart disease, peripheral vascular disease, aortapathy, atrial fibrillation or flutter, other CVD.
- \- Untreated serious mental illness (e.g, untreated psychosis).
Other
- Male Sex
- Currently Pregnant
Who the study is looking for
- Female Sex
- Age range 48-58 years
- In menopausal transition phase (pre-menopause or peri-menopause)
- Diagnosis of Type 2 Diabetes Mellitus
- Have access to and regularly use a smartphone with internet access
Age in the registry: 48 years to 58 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.